WO2008016661A3 - Morpholino compounds for treating inflammatory and demyelinating diseases and cancers - Google Patents

Morpholino compounds for treating inflammatory and demyelinating diseases and cancers Download PDF

Info

Publication number
WO2008016661A3
WO2008016661A3 PCT/US2007/017224 US2007017224W WO2008016661A3 WO 2008016661 A3 WO2008016661 A3 WO 2008016661A3 US 2007017224 W US2007017224 W US 2007017224W WO 2008016661 A3 WO2008016661 A3 WO 2008016661A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
treating inflammatory
demyelinating diseases
morpholino compounds
disorders
Prior art date
Application number
PCT/US2007/017224
Other languages
French (fr)
Other versions
WO2008016661A2 (en
Inventor
Alfred M Ajami
Original Assignee
Xanthus Pharmaceuticals Inc
Alfred M Ajami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xanthus Pharmaceuticals Inc, Alfred M Ajami filed Critical Xanthus Pharmaceuticals Inc
Publication of WO2008016661A2 publication Critical patent/WO2008016661A2/en
Publication of WO2008016661A3 publication Critical patent/WO2008016661A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) and a method of treating a patient suffering from certain inflammatory disorders, demyelinating disorders, FLT3-mediated disorders, CSF-I R-mediated disorders, cancers and leukemias, comprising administering to said patient a therapeutically effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided therein.
PCT/US2007/017224 2006-08-02 2007-08-02 Morpholino compounds for treating inflammatory and demyelinating diseases and cancers WO2008016661A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83506406P 2006-08-02 2006-08-02
US60/835,064 2006-08-02

Publications (2)

Publication Number Publication Date
WO2008016661A2 WO2008016661A2 (en) 2008-02-07
WO2008016661A3 true WO2008016661A3 (en) 2008-03-20

Family

ID=38792058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017224 WO2008016661A2 (en) 2006-08-02 2007-08-02 Morpholino compounds for treating inflammatory and demyelinating diseases and cancers

Country Status (1)

Country Link
WO (1) WO2008016661A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174674A1 (en) * 2015-04-27 2016-11-03 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
AU2017355603A1 (en) 2016-11-04 2019-06-20 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038999A1 (en) * 1996-04-12 1997-10-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Acridone-derived compounds useful as antineoplastic and antiretroviral agents
WO2001066545A2 (en) * 2000-03-07 2001-09-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY
WO2006081431A2 (en) * 2005-01-28 2006-08-03 Xanthus Pharmaceuticals, Inc. Compounds for treating inflammatory and demyelinating diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038999A1 (en) * 1996-04-12 1997-10-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Acridone-derived compounds useful as antineoplastic and antiretroviral agents
WO2001066545A2 (en) * 2000-03-07 2001-09-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 1,8-NAPHTHALIMIDE IMIDAZO[4,5,1-de]ACRIDONES WITH ANTI-TUMOR ACTIVITY
WO2006081431A2 (en) * 2005-01-28 2006-08-03 Xanthus Pharmaceuticals, Inc. Compounds for treating inflammatory and demyelinating diseases

Also Published As

Publication number Publication date
WO2008016661A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
DE60329001D1 (en) 8-hydroxychinolinderivate
MX2009006742A (en) Novel compounds.
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
MY147442A (en) Imidazoquinolines as lipid kinase inhibitors
WO2008033460A3 (en) Treating pain, diabetes, and lipid metabolism disorders
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
MX2009004096A (en) Talarazole metabolites.
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
UA85707C2 (en) Benzoxazines for treating respiratory tract diseases
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008048867A3 (en) Bicyclic heteroaromatic compounds
MX2009005691A (en) Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.
EP1817311A4 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
MX337396B (en) Method of treating polycystic kidney diseases with ceramide derivatives.
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2008009210A8 (en) Optical pure dihydropyrimidine compounds, their uses in the manufacture of a medicamnent for the treatment or the prevention of virosis diseases
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers
TW200736236A (en) Process for the manufacturing of pharmaceutically active compounds
GB0504103D0 (en) Novel method
WO2008023003A8 (en) Drug combinations for treating airway diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836428

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07836428

Country of ref document: EP

Kind code of ref document: A2